Research & Development

哥哥干哥哥射哥哥色28省份半年报:15省份增速超全国增速 湖南超越河北

發布時間︰

  白登山,最不缺的就是尸體!   “你想活嗎?”軍臣單于突然道。哥哥干   軍中的將士已經沒有多少戰意了,這是一件自然而然的事情。哥哥射   雲瑯不認為陰鷙的伊秩斜或者粗暴的於單敢在這個時候消耗他們仗以保身的軍隊。   “沒有那回事,騎兵的好處就在快捷,就在游擊,莫說人扛不住長時間的戰爭,就算是人能夠抗住,戰馬也受不了。平時我們可以揮刀劈砍五百次,到了軍陣上能全力劈出一百刀的就算是難得的好漢了。”哥哥色   彭春回頭看了一眼匈奴營帳嘆息一聲道︰“匈奴大軍已經整備妥當,不日就要大舉進攻,不知雲兄如何應對?”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.


Connect? Registries


The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo